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Association of increased Treg 
and Th17 with pathogenesis of 
moyamoya disease
Leihua Weng1,2, Xiang Cao1,3, Lijuan Han1,3, Haoran Zhao1,3, Shuwei Qiu1,3, Yaping Yan5, 
Xiaoying Wang6, Xiangyan Chen7, Weihong Zheng2, Xin Xu1,3, Yuanyuan Gao1,3, Yan Chen1,3, 
Jie Li8, Yongbo Yang1,3 & Yun Xu1,3,4
Immuno-inflammation has been shown to play a pivotal role in the pathogenesis of moyamoya disease 
(MMD). However, how did circulating Treg/Th17 cells involve in MMD patients remains unclear. 26 MMD, 
21 atherothrombotic stroke, and 32 healthy controls were enrolled in this study. MMD patients have a 
significantly higher percentage of circulating Treg and Th17 cells as well as their dominantly secreting 
cytokines than other groups (P < 0.0001), whereas no difference was found in the ratio of Treg/Th17 
between patients in MMD and atherothrombotic stroke group or control subjects (P = 0.244). However, 
the increased Treg in MMD patients which were enriched with FrIII Treg cells had deficient suppressive 
functions (P = 0.0017) compared to healthy volunteers. There was a positive correlation between 
Treg or TGF-β and MMD Suzuki’s stage. And the level of circulating Treg was as an independent factor 
associated with MMD stage. Besides, TGF-β was also correlated with the increased expression of VEGF 
in MMD patients. Our findings indicated an important involvement of circulating Treg in the pathogenic 
development of MMD and TGF-β in Treg induced VEGF.
Moyamoya disease (MMD) is a chronic steno-occlusive cerebrovascular disorder characterized by progressive 
stenosis of the terminal internal carotid artery (ICA) and/or its proximal branches, typically accompanied by 
an abnormally thin and fragile collateral vascular network at the base of the brain developed to compensate as 
the blood flow decreases in the affected area1. Accumulating studies showed that inflammation and autoim-
mune responses may be involved in the development of MMD2–4. Currently, imbalance of two unique CD4+T 
helper (Th) cell subsets, Treg and Th17 cells, has been implicated in the pathogenesis of a wide spectrum of auto-
immune and inflammatory diseases5, 6. Moreover, different Treg subsets with distinct functions were identified 
recently6–8. For example, CD4+CD25+FoxP3lowCD45RA−Tregs cells also named as Fraction (Fr) III Treg potent 
effector-Th cells capabilities9. However, whether Treg/Th17 cells are involved in the pathogenic development of 
MMD remains to be explored.
Vascular endothelial growth factor (VEGF) plays an essential role in the formation and maintenance of 
moyamoya vessels in MMD patients10. Interestingly, Treg have been shown to promoting angiogenesis via secret-
ing VEGFA in response to hypoxia11. Besides, Treg-produced transforming growth factor (TGF)-β1 could induce 
production of VEGF and stimulate subsequent angiogenesis12. Nonetheless, whether Treg/Th17 contribute to the 
production of VEGF and subsequent angiogenesis in development of MMD was unknown.
Therefore, we would like to investigate here whether imbalance of Treg/Th17 is associated with the course of 
MMD, and if so whether it contributes to abnormal angiogenesis in MMD through regulation of VEGF signaling. 
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Our results will clarify the importance of Treg/Th17s in the pathogenesis of MMD, thus providing a potential 
therapeutic target for MMD patients.
Materials and Methods
Patients. This study was approved by the ethics committee of the affiliated Drum Tower Hospital, Nanjing 
University Medical School, and all experiments were performed in accordance with relevant guidelines and reg-
ulations. Twenty-six inpatients diagnosed with definitive MMD by DSA according to the diagnostic criteria13 
were enrolled from the Department of Neurology and Neurosurgery of Drum Tower Hospital between 2013 and 
2014. After a detailed explanation of the study procedures, all participants or their guardians signed an informed 
consent form before the study. Patients who met any of the following criteria were excluded: 1) diagnosed with 
Quasi-moyamoya disease; 2) active intracranial hemorrhage including intracerebral hemorrhage, intraventricu-
lar hemorrhage, and subarachnoid hemorrhage; 3) patients were not suitable for DSA or MRI; 4) patients with 
severe infection and other disease which could influence inflammation and autoimmune responses. For controls 
we recruited twenty-one atherothrombotic stroke patients diagnosed by guidelines for diagnosis and therapy on 
Chinese patients with acute ischemic stroke14 and thirty-two age-matched healthy volunteers in this research. To 
minimize the effects of stroke on inflammation and autoimmune responses, heparinized whole blood samples of 
MMD and atherothrombotic stroke patients were collected at 48 ± 16.3 days after stroke which is believed as the 
recovery phase following ischemic stroke.
Flow cytometry. To investigate the changes of Treg and Th17 cells in MMD patients, flow cytometry was 
used to measure the percentage of Th17 and Treg cells. Briefly, peripheral blood mononuclear cells (PBMCs) 
were isolated from the fresh blood by Ficoll gradient centrifugation. For Th17 cells, the isolated PBMCs were 
pre-treated with phorbol 12-myristate-13-acetate (PMA, 25 ng/ml), ionomycin (50 µg/ml) and brefeldin-A(BFA, 
10 µg/ml, Enzo Life Sciences, Farmingdale, USA) at 37 °C for 4 h, then were collected and surface-stained with 
antibodies (eBiosicence, Frankfurk, Germany) at room temperature (RT) for 15 min, followed by fixed and per-
meabilized with the transcription factor staining buffer set kit according to the manufacturer’s protocol (eBi-
oscience), then intracellular-stained with IL-17 antibody (eBioscience) for 30 min. Treg and its subtypes were 
incubated with surface antibodies at RT for 15 min. After fixed and permeabilized, cells were stained with Foxp3 
antibody (eBiosicence) at RT for 30 min. Isotype controls were used in parallel. CD4+CD25+Foxp3+ cells were 
considered as Treg cells while CD3+CD8−IL-17+ cells were defined as Th17 cells. Cells were measured using flow 
cytometry (BD bioscience, San Diego, CA, USA). Data were analyzed using Flowjo software (Tree Star, Ashland, 
OR).
Cytometric Bead Array (CBA) and enzyme-linked immunosorbent assay (ELISA) assay. Next, 
to evaluate the role of Treg/Th17-driven inflammation, serum cytokines from Treg/Th17, Th1/Th2, and other 
inflammatory and angiogenenic factors, including interleukin (IL)-2, IL-4, IL-6, IL-10, IL-17, IL-23, tumor 
necrosis factor (TNF)-α, interferon (INF)-γ, VEGF, intercellular adhesion molecule (ICAM)-1 and vascular 
cell adhesion molecule (VCAM) were measured by Cytometric Bead Array (CBA, human inflammation kit, BD 
Biosciences) according to the manufacturer’s instructions. TGF-β and high-mobility group protein (HMGB)-1 
were measured by a commercially available ELISA (R&D Systems, Minneapolis, MN) according to the manufac-
turer’s instructions.
Cell purification and Treg suppressive assay. To determine whether the Treg from MMD have immu-
nosuppressive capacity, the proliferation effect of T cells was measured by flow cytometry. Treg cells were isolated 
using human CD4+CD25+Treg Isolation Kit (MiltenyiBiotec, Inc., Auburn, CA) according to the manufacturer’s 
instructions. The CD4+CD25− fraction was defined as effector T (Teff) cells. The Treg suppressive assay was con-
ducted as described before15. In brief, 5 * 104 carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled Teff 
cells (2.5 µM) per well were plated and cultured in a 24-well plate with Treg cells (Teff/Treg = 1:1) in the presence 
of CD3/CD28 antibodies (5 ng/ml), TGF-β (10 ng/ml) and IL-2 (100 IU/ml) for 96 h. The Teff cells were harvested 
and evaluated by flow cytometry. Cultured CD4+CD25− cells were taken as control group. The data were analyzed 
using Modfit software (Verity Software House 2.0, Top-sham, ME, USA).
Statistical Analysis. All samples and standards were assayed in triplicate. We used SPSS version 19.0 (SPSS 
Inc, New York, USA) to perform the statistical analyses. Shapiro-Wilk test was used to measure normality of 
data. Normal continuous variables were presented as mean ± S.D, while non-normal continuous variables were 
displayed as median and quartiles. Categorical variables were presented as percentages. For normal variables, 
Student’s t-test and one-way ANOVA were used to comparison between two groups and more than two groups, 
respectively. For non-normal variables, comparison between two groups and more than two groups was sta-
tistically evaluated by Mann-Whitney U-test and Kruskal-Wallis test, respectively. A multiple linear regression 
analysis was conducted for investigating the impact of Treg, Th17, TGF-β, IL-10 and IL-17 on the serum VEGF. 
Correlation of the inflammatory and angiogenic factors with the severity of MMD was evaluated by Spearman 
correlation coefficient (r). The predictive value of serum cytokines on the severity of MMD was tested by binary 
of logistic regression analysis. A P value < 0.05 was considered statistically significant.
Results
Clinical features of patients. Between Jan 2013 and Dec 2014, a total of 26 consecutive patients with 
MMD (10 females and 16 males), 21 patients with atherothrombotic stroke (8 females and 13 males) and 32 
age-matched healthy volunteers (19 females and 13 males) as controls were enrolled into our cohort. General 
clinical features of control group, MMD and atherothrombotic stroke patients are summarized in Table 1. The 
common initial presentations in MMD patients was ischemic stroke in our study (46.15%) followed by cerebral 
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hemorrhage (26.92%), subarachnoid hemorrhage (23.08%) and TIA (3.85%, Table 2). The majority of patients 
were presented at Suzuki Angiographic stage 4 and 5 (53.84% and 23.08%, respectively) and 92.3% of patients had 
bilateral lesions. Besides, there was no significant difference in leukocyte count and C-reactive protein (CRP)-
levels among MMD, atherothrombotic stroke and controls (data not shown).
Increased peripheral Treg and Th17 in MMD patients. Compared to control, the serum protein level 
of several inflammatory molecules including HMGB-1, ICAM-1 and VCAM in MMD patients was strikingly 
increased by 92.32% [57.000 (34.000, 154.000) vs. 27.000 (13.500, 61.000), P < 0.05], 31.66% [38.070 (31.750, 
42.760) vs. 28.080 (21.280, 34.905), P < 0.01] and 51.5% [158.135 (130.560, 211.360) vs. 103.975 (85.435, 135.810), 
P < 0.001], respectively. (Supplementary Fig. 1) These findings indicate that peripheral inflammatory responses 
were induced in MMD patients.
To clarify whether imbalance of peripheral Treg/Th17 is involved in the pathophysiology of MMD, the per-
centage of Treg and Th17 cells from circulating CD4+ T cells and their dominantly secreting inflammatory 
cytokines were measured in MMD patients and control. Results showed that Treg and Th17 were significantly 
increased in MMD patients [4.615 (3.530, 7.240) and 2.440 (1.740, 3.990)] compared to atherothrombotic stroke 
[2.370 (1.550, 2.680), P < 0.0001 and 1.490 (1.090, 1.690), P < 0.0001)] or healthy control group [2.525 (2.040, 
3.350), P < 0.0001 and 1.215 (0.825, 1.695), P < 0.0001] (Fig. 1A,B). However, there was no difference in the ratio 
of Treg/Th17 among the three groups (P = 0.244, Fig. 1C).
In consistent, serum expression of Treg-related TGF-β and IL-10 was enhanced by 121.67% [34.262 (28.016, 
45.254) vs. 16.973 (12.117, 19.643), P < 0.001] and 8.83% [12.855 (12.210, 13.620) vs. 12.000 (11.155, 12.860), 
P = 0.0029] in MMD patients compared with control. Similarly, Th17-related IL-17, TNF-α, IL-6 and IL-23 were 
significantly higher than control by 57.94% [130.655 (99.710, 150.030) vs. 78.565 (74.070, 85.455), P < 0.001], 
7.33% [16.680 (15.870, 17.620) vs. 15.970 (14.500, 16.835), P < 0.05], 92.52% [8.420 (7.130, 11.770) vs. 5.285 
(2.855, 7.265), P < 0.001] and 39.47% [10.925 (8.200, 15.800) vs. 8.185 (6.950, 9.575), P < 0.01] in MMD patients, 
respectively (Supplement Fig. 1). Nevertheless, the level of Th1/Th2-related cytokines, such as IL-2, IL-4, and 
INF-γ was not significantly different between the two groups [IL-2: 6.860 (5.930, 8.280) vs. 6.660 (5.630, 8.180), 
P = 0.9271; IL-4: 11.210 (9.720, 12.370) vs. 10.560 (9.180, 12.430), P = 0.8562; INF-γ: 14.030 (13.580, 15.000) vs. 
13.840 (13.160, 14.675), P = 0.5483].
Decreased suppressive function of peripheral Treg in MMD patients. Since no difference was found 
in the ratio of Treg/Th17, we further investigated whether suppressive function of Treg in MMD patients was 
altered. Interestingly, we found that the Treg from MMD patients had a lower suppressive function compared to 
those from control using proliferative assay (91.81 ± 0.6439 vs 85.84 ± 0.9120, P = 0.0017, Fig. 2A).
Different Treg subsets have been shown to potent distinct functions. We therefore further measured changes 
in the percentage of three major Treg subtypes. The results showed that the percentage of FrIII Treg cells among 
CD4+CD25+ T cells and CD4+CD25+FoxP3+Tregs were significantly elevated in MMD patients compared to 
Normal (N = 32) MMD (N = 26) Stroke (N = 21)
Age 38.50 ± 0.6720 44.08 ± 1.860 64.62 ± 8.077
Gender (F/M) 19/13 10/16 8/13
Hypertension 0/32 8/26 16/21
Diabetes Mellitus 0/32 3/26 7/21
Autoimmune Disease 0/32 0/26 0/21
Table 1. Clinical characteristics of control group, MMD and atherothrombotic stroke.




Cerebral hemorrhage 7 (26.92%)
SAH 6 (23.08%)








Table 2. Initial symptom and Suzuki’s angiographic stage of MMD. SAH: subarachnoid hemorrhage.
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control (10.88 ± 0.8052 vs 7.324 ± 0.4782 among CD4+, P = 0.0018; 59.86 ± 2.095 vs 50.74 ± 2.238 among Treg, 
P = 0.0184, Fig. 2B,C). However, the proportion of FrI Treg among total Treg was markedly decreased in MMD 
patients (19.17 ± 0.8452 vs 28.37 ± 2.456 among Treg, P = 0.0126). Meanwhile, no significant difference was 
found in the proportion of FrII Treg cells between the two groups (3.876 ± 0.5328 vs 3.269 ± 0.2573 among CD4+, 
P = 0.2733; 20.97 ± 1.755 vs 22.52 ± 0.9697 among Treg, P = 0.4172). FrIII Treg cells are lack of suppressive func-
tions. These findings suggested that Treg which induced inflammation and lacked suppressive capacity of T cells 
resulted from increasing FrIII Treg in MMD patients.
Increased serum expression of VEGF in MMD patients. Moreover, the serum protein expression 
of angiogenic factor, VEGF was significantly increased by five folds [29.060 (13.910, 63.150) vs. 7.360 (5.325, 
10.035), P < 0.0001] in MMD patients compared to control, which was consistent with previous findings16. 
Intriguingly, results of the multiple linear regression analysis showed that TGF-β had a correlation with VEGF 
(P < 0.01, Table 3).
Figure 1. The percentage of peripheral Treg and Th17 cells in MMD patients, atherothrombotic stroke patients 
and controls. Both the levels of Treg and Th17 were significantly increased in MMD patients compared to other 
groups. (A,B) Representative FACS plots for Treg and Th17 cells in peripheral blood. (C) The ratio of Treg/Th17 
among the three groups. (D) Each bar represents the median and quartiles of three independent experiments. 
*P < 0.05, **P < 0.01 and ***P < 0.001.
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Treg and TGF-β is associated with the pathophysiology of MMD. Finally, we investigated the cor-
relation of the inflammatory and angiogenic factors with the severity of MMD. 26 MMD patients were divided 
into 3 grades based on the Suzuki’s angiographic stage of MMD: grade 1 (Suzuki’s stage 1 and 2, n = 2), grade 2 
(Suzuki’s stage 3 and 4, n = 15) and grade 3 (Suzuki’s stage 5 and 6, n = 9). The results suggested that the Suzuki’s 
angiographic stage is positively correlated with the level of Treg, TGF-β and the ratio of Treg/Th17, but not Th17 
and IL-17 (Table 4). To investigate the predictive role of serum Treg and TGF-β for the severity of MMD, binary 
logistic regression analysis was used. And the results showed that the higher level of Treg could be considered as 
an predictive factor of (OR 3.842, 95% CI 1.093-13.505) grade 3, compared to grade 2, of MMD after adjusting 
TGF-β (Table 5). However, these factors had no relationship with onset symptoms and gender.
Figure 2. The proliferation of CD4+CD25− T cells co-cultured with Treg (A). The suppressive function of 
Treg isolated from MMD patients was lower than controls. The changes of Treg subtypes in MMD patients and 
healthy controls. Both the percentage of FrIII Treg cells among CD4+CD25+ T cells (B) and total Treg cells (C) 
were significantly elevated in MMD patients. FACS plots for subtypes of Treg cells in MMD patients and healthy 
controls (D). Each bar represents the mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01 
vs. normal Treg cells group, ##P < 0.01 vs. control group.
B S.E. 95% CI Sig.
Treg 0.632 2.074 −3.53–4.794 0.762
Th17 −2.298 3.332 −8.984–4.388 0.494
TGF-β 0.929 0.277 0.372–1.486 0.002**
IL-10 1.561 2.501 −3.457–6.578 0.535
IL-17 0.088 0.083 −0.079–0.255 0.295
Table 3. The correlation of serum VEGF levels with various parameters by linear regression analysis. B, 
coefficients; S.E. : SEM; **P < 0.01.
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Discussion
Here, for the first time, we reported: 1) Circulating Treg and Th17 cells were higher in MMD patients than that in 
atherothrombotic stroke and healthy controls. 2) The dominantly expressed FrIII Treg subset in MMD patients may 
be responsible for the deficient suppressive function of Treg. 3) TGF-β had a positive relationship with VEGF. 4) 
Treg is an independent factor associated with MMD Suzuki’s angiographic stage.
In the present study, the ratio of Treg/Th17 was not significantly different between MMD patients and control 
subjects. However, Treg from MMD patients showed deficient suppressive functions. We believed that func-
tion imbalance in Treg/Th17 may contribute to the pathophysiology of MMD, since imbalance of Treg/Th17 is 
involved in several human autoimmune diseases and Treg depletion can evoke autoimmunity17–20. Suppressive 
function of Treg cells have been found to be defective in several other autoimmune diseases such as psoriasis21, 
type 1 diabetes mellitus (DM)22 and multiple sclerosis (MS)23. Subsequently, we found that increased Tregs were 
enriched with FrIII Tregs. Accumulating evidence have recently shown that Treg possess high plasticity and can 
acquire functions of effector-like Th cells, lose their suppressive function but secrete pro-inflammatory cytokines, 
including IL-1724, 25. Three distinct Treg subpopulations with different functions in human FoxP3+Tregs have 
been identified. CD4+ CD25+ FoxP3low CD45RA+Tregs (FrI, stable resting Treg), CD4+ CD25+ FoxP3high 
CD45RA−Tregs (FrII, activated Treg) and CD4+CD25+FoxP3lowCD45RA−Tregs cells (FrIII, unstable Treg). The 
FrI and FrII Treg are suppressive9, while FrIII Treg are lack of suppressive functions but possess some features 
of these “ex-Treg” and may be in the process of transforming into Th17 cells. Therefore, in the present study, the 
increased FrIII Tregs may be responsible for the decreased suppressive functions of Tregs in MMD patients.
C-reactive protein (CRP) is often used as a clinical marker of acute systemic inflammation. In this research, 
all blood samples of patients were collected at stable phase after stroke and the plasma concentration of CRP 
shows no significant difference among MMD, atherothrombotic stroke and control group (data not shown). We 
further found that both of the Treg/Th17 cells dominantly expressed cytokines including IL-10, TGF-β, IL-17, 
IL-6 and IL-23 were higher in MMD patients than controls. Moreover, IL-2, IL-4 and INF-γ, which are mainly 
from Th1/Th2, had no significant differences. They could mediate immune and inflammatory responses in several 
autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 DM, MS, 
allergy, parasitosis, asthma, et al.26, 27. It suggests that the immune response of MMD is not completely consistent 
with SLE, RA, and so on. Treg/Th17-mediated autoimmune responses and inflammation may contribute to the 
pathogenesis of MMD.
In addition, HMGB-1, a late-acting pro-inflammatory cytokine, plays an important role and shows aberrant 
high level in chronic inflammatory diseases such as RA and SLE28. In this study, MMD patients had a higher 
serum level of HMGB-1 than controls, which is consistent with patients with chronic inflammatory diseases.
Consistent with previous findings, we also found that the serum level of VEGF in MMD patients was dramat-
ically higher than controls16, 29. The increased level of VEGF in MMD may be subjected to upregulated levels of 
Treg cells and Th17 cells. Treg have been shown to secrete VEGFA in response to hypoxia, which plays a critical 
role in forming a VEGFA-rich microenvironment and promoting angiogenesis11, while IL-17 has been impli-
cated in upregulating VEGF and promoting VEGFR expression30, 31. Therefore, Treg/Th17 cells may promote 
Grade 2 (N = 15) Grade 3 (N = 9) P value
Treg 3.745 (2.813, 4.598) 5.420 (4.088, 7.443) 0.0068**
Th17 2.170 (1.650, 3.450) 2.450 (1.785, 3.340) 0.7526
TGF-β 31.730 (28.020, 41.470) 48.250 (30.800, 64.190) 0.0112*
IL-17 129.800 (95.800, 146.000) 121.100 (93.390, 153.900) 0.8537
Treg/Th17 1.825 (0.697, 2.222) 2.746 (1.312, 3.132) 0.0401*
IL-10 12.830 (11.900, 14.740) 13.150 (12.490, 13.760) 0.8567
IL-6 8.420 (7.450, 11.770) 8.420 (5.985, 17.350) 0.5466
IL-23 12.280 (7.770, 15.800) 9.650 (7.520, 17.560) 0.9844
TNF-α 16.740 (15.870, 18.500) 16.680 (15.720, 17.310) 0.3745
VEGF 33.450 (13.910, 63.150) 28.760 (17.940, 68.760) 0.7744
ICAM-1 38.600 (31.750, 49.650) 35.350 (26.490, 39.800) 0.1294
VCAM 187.900 (143.000, 222.000) 132.600 (99.470, 210.900) 0.1771
HMGB-1 59.000 (25.500, 106.000) 66.000 (35.000, 185.000) 0.3284
Table 4. Correlations between Treg/Th17 and relevant cytokines and the Suzuki’s angiographic stage. Notes: 
Correlation is significant at the 0.05 level. *P < 0.05, **P < 0.01.
B S.E. Sig. Exp(B)
95% CI for 
Exp (B)
Treg 1.346 0.641 0.036* 3.842 1.093–13.505
TGF-β 0.14 0.074 0.059 1.151 0.995–1.331
Constant −12.153 5.214 0.02 0
Table 5. The effects of Treg and TGF-βon Suzuki’s angiographic stage by binary logistic regression analysis. B, 
coefficients; SE, SEM; Exp(B), OR; *P < 0.05.
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angiogenesis of MMD by upregulating the expression of VEGF. In addition, Treg-produced TGF-β1 can also 
induce production of VEGF and stimulate subsequent angiogenesis12. In our study, the increased TGF-β was 
associated with the VEGF, which indicated that TGF-β may promote the vascular endothelial cell proliferation 
leading to abnormal vessels hyperplasia in MMD.
However, there are several limitations in this study. First, this is a preliminary study. The sample size is small. 
Secondly, TGF-β is not specifically expressed by Treg cells. In our future study, we need enroll more patients. 
To clarify the relationship of TGF-β and VEGF or MMD stage, level of TGF-β expressed by Treg shouled be 
measured.
Summary
In conclusion, our research sheds new light on the involvement of Treg/Th17 cells in the pathogenesis of MMD, 
thereby providing a potential therapeutic target for treatment of MMD patients. A larger number of patients and 
control subjects should be recruited in the future studies to validate findings in this study.
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